Last reviewed · How we verify
NCT05738447
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
Status unknown
Phase 1
Last updated 22 February 2023
What this trial tests
Phase 1 trial testing HBV mRNA vaccine in Liver Cancer in 9 participants. Status unknown.
Timeline
15 February 2023
Primary endpoint
1 January 2024
1 January 2024
1 January 2025
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 15 February 2023 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- HBV mRNA vaccine — full drug profile →
Conditions studied
- Liver Cancer — all drugs for Liver Cancer →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
West China Hospital
Who can join
Adults 18 to 70, any sex, with Liver Cancer or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.
Wang YS, Kumari M, Chen GH, Hong MH, et al · · 2023 · cited 93× · PMID 37805495 · DOI 10.1186/s12929-023-00977-5 -
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.
Wang B, Pei J, Xu S, Liu J, et al · · 2023 · cited 72× · PMID 37744371 · DOI 10.3389/fimmu.2023.1246682 -
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.
Shi Y, Shi M, Wang Y, You J. · · 2024 · cited 67× · PMID 39543114 · DOI 10.1038/s41392-024-02002-z -
Recent progress in mRNA cancer vaccines.
Yao R, Xie C, Xia X. · · 2024 · cited 57× · PMID 38282471 · DOI 10.1080/21645515.2024.2307187 -
Viral oncogenesis in cancer: from mechanisms to therapeutics.
Xiao Q, Liu Y, Li T, Wang C, et al · · 2025 · cited 45× · PMID 40350456 · DOI 10.1038/s41392-025-02197-9 -
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.
Tojjari A, Saeed A, Singh M, Cavalcante L, et al · · 2023 · cited 37× · PMID 37631925 · DOI 10.3390/vaccines11081357 -
Advances in mRNA-Based Cancer Vaccines.
Ni L. · · 2023 · cited 33× · PMID 37897001 · DOI 10.3390/vaccines11101599 -
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.
Haghighi E, Abolmaali SS, Dehshahri A, Mousavi Shaegh SA, et al · · 2024 · cited 28× · PMID 39543630 · DOI 10.1186/s12951-024-02972-w
Verify or expand the search:
- PubMed search for NCT05738447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HBV mRNA vaccine
Trials testing the same drug.
- NCT07077356 — Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma · Phase 1 · recruiting
Other recruiting trials for Liver Cancer
Currently open trials in the same condition.
- NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05738447 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 22 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05738447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing